Changes in Senior Management Personnel
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs reported audited standalone net profit of Rs 1,116.40 million for FY2026, down from Rs 1,609.98 million in FY2025 (a 31% decline). Revenue from operations grew marginally to Rs 13,487.36 million from Rs 13,117.84 million. The Board recommended a final dividend of Rs 1 per share plus a special dividend of Rs 2 per share, totaling Rs 3 per share for FY2026, subject to shareholder approval. In senior management changes, Mr. V Jagannathan has been appointed as President - HR (Senior Management Personnel), succeeding Mr. Arvind Srivastava who has ceased to be President - HR effective May 14, 2026. The filing also notes ongoing Income Tax Department proceedings from a January 2025 search operation, with show cause notices received but no material adjustments made to financials yet.
The profit decline may concern investors, though the special dividend signals management confidence. The HR leadership change appears routine with a smooth transition in place. The pending tax matter remains an open risk factor.